Q1 Earnings Forecast for NERV Issued By HC Wainwright

Minerva Neurosciences, Inc (NASDAQ:NERV) – Stock analysts at HC Wainwright issued their Q1 2026 earnings estimates for shares of Minerva Neurosciences in a research note issued on Thursday, November 6th. HC Wainwright analyst D. Tsao anticipates that the biopharmaceutical company will earn ($0.14) per share for the quarter. HC Wainwright has a “Neutral” rating and a $4.00 price target on the stock. The consensus estimate for Minerva Neurosciences’ current full-year earnings is ($0.30) per share. HC Wainwright also issued estimates for Minerva Neurosciences’ Q2 2026 earnings at ($0.15) EPS, Q3 2026 earnings at ($0.16) EPS, Q4 2026 earnings at ($0.09) EPS and FY2029 earnings at $0.61 EPS.

Minerva Neurosciences (NASDAQ:NERV) last issued its quarterly earnings results on Wednesday, November 5th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.01).

Separately, Weiss Ratings reissued a “sell (d+)” rating on shares of Minerva Neurosciences in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Reduce” and a consensus price target of $4.00.

Minerva Neurosciences Price Performance

Shares of NERV stock traded down $0.01 during mid-day trading on Friday, hitting $3.64. The stock had a trading volume of 12,111 shares, compared to its average volume of 903,824. Minerva Neurosciences has a 12-month low of $1.15 and a 12-month high of $12.46. The firm’s 50-day moving average is $2.84 and its two-hundred day moving average is $2.17.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Minerva Neurosciences stock. Apella Capital LLC lifted its position in Minerva Neurosciences, Inc (NASDAQ:NERV) by 87.8% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 39,314 shares of the biopharmaceutical company’s stock after acquiring an additional 18,375 shares during the period. Apella Capital LLC’s holdings in Minerva Neurosciences were worth $83,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 34.56% of the stock is owned by hedge funds and other institutional investors.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.